Finance

Beta
Lists
ARGX:NASDAQ
argenx SE - ADR
$852.50
-0.11%
(-0.90) 1D
$852.50
0.00% (0.00)
After hours
Closed: Jun 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARGX...
Open
$869.85
High
$878.03
Low
$837.74
Mkt. cap
57.67B
Avg. vol.
347.51K
Volume
0.00
P/E ratio
37.88
52-wk high
$934.62
52-wk low
$510.06
EPS
$22.51
Beta
0.47
Shares outstanding
61.88M
No. of employees
2K
Open
$869.85
High
$878.03
Low
$837.74
Mkt. cap
57.67B
Avg. vol.
347.51K
Volume
0.00
P/E ratio
37.88
52-wk high
$934.62
52-wk low
$510.06
EPS
$22.51
Beta
0.47
Shares outstanding
61.88M
No. of employees
2K
News stories
From sources across the web
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About argenx SE - ADR
CEO-
Employees1.86K
Founded2008
Headquarters-
SectorBiotechnology
Websiteargenx.com
Analyst Ratings
Based on 18 analysts giving stock ratings to ARGX in the past 3 months
Strong Buy
Buy
17
Hold
1
Sell
0
12 month forecast
Based on 18 Wall Street analysts offering 12 month price targets for ARGX in the last 3 months.
Highest
Current $852.50
$1,291.00 (+51.44%)
Average
$1,067.73 (+25.25%)
Lowest
$850.00 (-0.29%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Danielle Brill
Truist Financial
Buy
Maintained
-
-
06/24/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
$1,180.00
+38.4%
06/24/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$1,014.00
+18.9%
06/24/2026
Yaron Werber
TD Cowen
Buy
Reiterated
$1,146.00
+34.4%
06/23/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$1,135.00
+33.1%
06/24/2026
Myles Minter
William Blair
Buy
Maintained
-
-
06/24/2026
Unknown Analyst
Wedbush
Buy
Maintained
$1,000.00
+17.3%
06/24/2026
Derek Archila
Wells Fargo
Buy
Maintained
$1,291.00
+51.4%
06/17/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
$1,016.00
+19.2%
06/16/2026
David Nierengarten
Wedbush
Buy
Maintained
$1,000.00
+17.3%
06/15/2026
Unknown Analyst
William O'Neil
Buy
Initiated
-
-
06/08/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$940.00
+10.3%
06/04/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Reiterated
$1,255.00
+47.2%
05/29/2026
Luca Issi
RBC Capital
Buy
Maintained
$890.00
+4.4%
05/27/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Reiterated
$1,059.00
+24.2%
05/15/2026
Samantha Semenkow
Citi
Buy
Reiterated
$1,152.00
+35.1%
05/12/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$1,075.00
+26.1%
05/11/2026
Unknown Analyst
Jefferies
Buy
Maintained
$1,013.00
+18.8%
05/08/2026
Xian Deng
UBS
Hold
Maintained
$850.00
-0.3%
05/08/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
05/07/2026
Colleen M. Kusy
Robert W. Baird
Hold
Maintained
$867.00
+1.7%
02/27/2026
Jason Butler
Citizens JMP
Buy
Maintained
$944.00
+10.7%
02/27/2026
Rajan Sharma
Goldman Sachs
Buy
Maintained
$910.00
+6.7%
02/26/2026
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (EUR)
€4.70 / €4.19
+11.98%beat
Revenue / Est. (EUR)
1.12B / 1.12B
-0.26%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
967.19M
1.15B
1.31B
1.31B
Cost of goods sold
438.44M
465.08M
521.40M
564.00M
Cost of revenue
438.44M
465.08M
521.40M
564.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
324.90M
336.29M
429.62M
355.00M
Operating expense
324.90M
336.29M
429.62M
355.00M
Total operating expenses
763.35M
801.37M
951.02M
919.00M
Operating income
203.84M
349.97M
359.56M
394.00M
Other non operating income
-
-
-907.00K
-
EBT including unusual items
286.90M
386.05M
403.29M
426.00M
EBT excluding unusual items
286.90M
386.05M
391.71M
426.00M
Income tax expense
41.54M
41.80M
-129.66M
60.00M
Effective tax rate
14.48%
10.83%
-32.15%
14.08%
Other operating expenses
-
-
-
-
Net income
245.36M
344.26M
532.95M
366.00M
Net profit margin
25.37%
29.90%
40.67%
27.88%
Earnings per share
-
-
-
-
Interest and investment income
38.40M
42.70M
44.95M
44.00M
Interest expense
-1.13M
-993.00K
-
-1.00M
Net interest expenses
37.27M
41.71M
44.95M
43.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
210.47M
350.35M
361.38M
395.82M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer